LONG TERM EFFICACY AND SAFETY OF ADALIMUMAB IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) ASSOCIATED UVEITIS

D. Lazarević, Marija Ratković Janković, M. Jakovljević, J. Vojinović
{"title":"LONG TERM EFFICACY AND SAFETY OF ADALIMUMAB IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) ASSOCIATED UVEITIS","authors":"D. Lazarević, Marija Ratković Janković, M. Jakovljević, J. Vojinović","doi":"10.5633/amm.2021.0304","DOIUrl":null,"url":null,"abstract":"In the last decade, tumor necrosis factor- (TNF-) inhibitors have shown excellent control of ocular inflammation in juvenile idiopathic arthritis (JIA)-associated uveitis. We have retrospectively evaluated the long-term efficacy and safety of adalimumab in 19 biologically naive patients with JIA-associated uveitis from our biologic registry. Demographic data and blood samples were collected at different time points. Uveitis activity was evaluated by slit-lamp biomicroscopy. Adverse events were recorded. The registry records provided a ten-year follow-up of 11 (57.90%) female patients diagnosed with oligo/extended oligoarticular JIA-associated uveitis and 8 (42.10%) males diagnosed with enthesitis-related arthritis (ERA) with uveitis. Adalimumab was the first biologic prescribed to JIA patients with active uveitis that failed to respond to standard treatment. A tenyear long follow-up period has shown that there were no new relapsis of uveitis while patients were receiving adalimumab and metotrexate. All of our patients after adalimumab introduction were able to gradually tapper and stop treatment with topical steroids. Thirty-six point eighty-four percent of our patients were able to stop biological treatment 36 months after adalimumab commencing. Uveitis has relapsed three monts after the adalimumab discontinuation only in two patients (10.53%). No serious adverse events were recorded. Thirty-one point fifty-eight percent of patients expirienced minor adverse events. During a long-term follow-up, adalimumab showed good efficacy and safety profile in JIA patients with active inflammatory ocular disease. Acta Medica Medianae 2021;60(3):30-36.","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Medianae","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5633/amm.2021.0304","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In the last decade, tumor necrosis factor- (TNF-) inhibitors have shown excellent control of ocular inflammation in juvenile idiopathic arthritis (JIA)-associated uveitis. We have retrospectively evaluated the long-term efficacy and safety of adalimumab in 19 biologically naive patients with JIA-associated uveitis from our biologic registry. Demographic data and blood samples were collected at different time points. Uveitis activity was evaluated by slit-lamp biomicroscopy. Adverse events were recorded. The registry records provided a ten-year follow-up of 11 (57.90%) female patients diagnosed with oligo/extended oligoarticular JIA-associated uveitis and 8 (42.10%) males diagnosed with enthesitis-related arthritis (ERA) with uveitis. Adalimumab was the first biologic prescribed to JIA patients with active uveitis that failed to respond to standard treatment. A tenyear long follow-up period has shown that there were no new relapsis of uveitis while patients were receiving adalimumab and metotrexate. All of our patients after adalimumab introduction were able to gradually tapper and stop treatment with topical steroids. Thirty-six point eighty-four percent of our patients were able to stop biological treatment 36 months after adalimumab commencing. Uveitis has relapsed three monts after the adalimumab discontinuation only in two patients (10.53%). No serious adverse events were recorded. Thirty-one point fifty-eight percent of patients expirienced minor adverse events. During a long-term follow-up, adalimumab showed good efficacy and safety profile in JIA patients with active inflammatory ocular disease. Acta Medica Medianae 2021;60(3):30-36.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿达木单抗治疗青少年特发性关节炎相关葡萄膜炎的长期疗效和安全性
在过去的十年中,肿瘤坏死因子-(TNF-)抑制剂对青少年特发性关节炎(JIA)相关葡萄膜炎的眼部炎症有很好的控制作用。我们回顾性地评估了阿达木单抗在19例生物学上初治的jia相关性葡萄膜炎患者中的长期疗效和安全性。在不同时间点采集人口统计数据和血液样本。用裂隙灯生物显微镜观察葡萄膜炎的活动性。记录不良事件。注册记录提供了10年的随访,其中11例(57.90%)女性诊断为少/扩展少关节jia相关葡萄膜炎,8例(42.10%)男性诊断为关节炎相关(ERA)伴葡萄膜炎。阿达木单抗是首个给标准治疗无效的活动性葡萄膜炎JIA患者开的生物制剂。一个长达十年的随访期表明,当患者接受阿达木单抗和甲氨蝶呤治疗时,没有新的葡萄膜炎复发。我们所有的患者在引入阿达木单抗后都能够逐渐减少和停止局部类固醇治疗。36.84%的患者在阿达木单抗开始治疗36个月后能够停止生物治疗。只有2例患者(10.53%)在阿达木单抗停药3个月后葡萄膜炎复发。无严重不良事件记录。31.58%的患者出现了轻微的不良事件。在长期随访中,阿达木单抗在伴有活动性炎性眼病的JIA患者中显示出良好的疗效和安全性。医学学报,2021;60(3):30-36。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
11
审稿时长
16 weeks
期刊最新文献
FEATURES OF THE INNATE IMMUNE RESPONSE DURING THE SARS-COV-2 INFECTION MORPHOMETRIC ANALYSIS OF BICEPS MUSCLE TISSUE OBTAINED FROM RATS ACUTELY EXPOSED TO CARBON-TETRACHLORIDE PAIN MANAGEMENT OF SENSORIMOTOR POLYNEUROPATHY IN COVID-19 INFECTIONS APPLYING NEURAL NETWORKS TO HEALTH CARE QUALITY PARAMETERS CENTRAL SENSITIZATION INVENTORY SCORES IN PATIENTS WITH NEUROPATHIC PAIN COMPARED TO HEALTHY SUBJECTS
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1